205 related articles for article (PubMed ID: 22311477)
1. Adenosine A1 receptor regulates osteoclast formation by altering TRAF6/TAK1 signaling.
He W; Cronstein BN
Purinergic Signal; 2012 Jun; 8(2):327-37. PubMed ID: 22311477
[TBL] [Abstract][Full Text] [Related]
2. 2-Methoxystypandrone represses RANKL-mediated osteoclastogenesis by down-regulating formation of TRAF6-TAK1 signalling complexes.
Chiou WF; Liao JF; Huang CY; Chen CC
Br J Pharmacol; 2010 Sep; 161(2):321-35. PubMed ID: 20735418
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling.
Tomomura M; Suzuki R; Shirataki Y; Sakagami H; Tamura N; Tomomura A
PLoS One; 2015; 10(6):e0130174. PubMed ID: 26083531
[TBL] [Abstract][Full Text] [Related]
5. (+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation.
Chiou WF; Huang YL; Liu YW
PLoS One; 2014; 9(2):e89159. PubMed ID: 24558484
[TBL] [Abstract][Full Text] [Related]
6. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
[TBL] [Abstract][Full Text] [Related]
7. TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis.
Lamothe B; Lai Y; Xie M; Schneider MD; Darnay BG
Mol Cell Biol; 2013 Feb; 33(3):582-95. PubMed ID: 23166301
[TBL] [Abstract][Full Text] [Related]
8. Regulation of RANKL-induced osteoclastogenesis by TGF-β through molecular interaction between Smad3 and Traf6.
Yasui T; Kadono Y; Nakamura M; Oshima Y; Matsumoto T; Masuda H; Hirose J; Omata Y; Yasuda H; Imamura T; Nakamura K; Tanaka S
J Bone Miner Res; 2011 Jul; 26(7):1447-56. PubMed ID: 21305609
[TBL] [Abstract][Full Text] [Related]
9. Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL.
Huang H; Ryu J; Ha J; Chang EJ; Kim HJ; Kim HM; Kitamura T; Lee ZH; Kim HH
Cell Death Differ; 2006 Nov; 13(11):1879-91. PubMed ID: 16498455
[TBL] [Abstract][Full Text] [Related]
10. Gingipains promote RANKL-induced osteoclastogenesis through the enhancement of integrin β3 in RAW264.7 cells.
Mo W; Luo H; Wu J; Xu N; Zhang F; Qiu Q; Zhu W; Liang M
J Mol Histol; 2020 Apr; 51(2):147-159. PubMed ID: 32193744
[TBL] [Abstract][Full Text] [Related]
11. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways.
Zhang YH; Heulsmann A; Tondravi MM; Mukherjee A; Abu-Amer Y
J Biol Chem; 2001 Jan; 276(1):563-8. PubMed ID: 11032840
[TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
14. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
15. Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.
Chen K; Yan Z; Wang Y; Yang Y; Cai M; Huang C; Li B; Yang M; Zhou X; Wei X; Yang C; Chen Z; Zhai X; Li M
Biomed Pharmacother; 2020 Jun; 126():110067. PubMed ID: 32272431
[TBL] [Abstract][Full Text] [Related]
16. Melittin inhibits osteoclast formation through the downregulation of the RANKL-RANK signaling pathway and the inhibition of interleukin-1β in murine macrophages.
Choe JY; Kim SK
Int J Mol Med; 2017 Mar; 39(3):539-548. PubMed ID: 28204822
[TBL] [Abstract][Full Text] [Related]
17. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
[TBL] [Abstract][Full Text] [Related]
18. Rolofylline, an adenosine A1 receptor antagonist, inhibits osteoclast differentiation as an inverse agonist.
He W; Wilder T; Cronstein BN
Br J Pharmacol; 2013 Nov; 170(6):1167-76. PubMed ID: 23962057
[TBL] [Abstract][Full Text] [Related]
19. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
20. Regulation of RANKL-induced osteoclastogenesis by RING finger protein RNF114.
Lin B; Ke Q; Leaman DW; Goel V; Agarwal A
J Orthop Res; 2018 Jan; 36(1):159-166. PubMed ID: 28708287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
